EL7.AI
StocksMedium•12 August 2026•
1 min read

Lenz Therapeutics Beats Q2 Revenue Estimates by 148% Driven by VIZZ Sales

Key Facts

1Lenz Therapeutics reported Q2 revenues of $5.5 million, significantly beating analyst estimates by 148.24%.
2The company posted a loss of $1.02 per share, which was narrower than expected.
3Piper Sandler lowered its price target for Lenz Therapeutics to $7.00 from a previous $12.00.

In a move reflecting the accelerating growth within the specialized pharmaceutical sector, Lenz Therapeutics announced robust financial results for the second quarter of 2026. According to reports, the company generated $5.5 million in revenue, significantly beating analyst estimates by 148.24%, driven by the commercial launch of its VIZZ treatment and licensing agreements. The company also posted a loss of $1.02 per share, which was narrower than previously anticipated.

This strong performance was primarily fueled by $3.8 million from license agreements and $1.7 million in product sales, with approximately 27,000 monthly packs of VIZZ sold, marking a 9% volume increase over the first quarter. Despite these positive results, Piper Sandler lowered its price target for LENZ to $7.00 from $12.00, as the stock has traded between a 52-week low of $4.68 and a high of $50.40.

Looking ahead, the company is focusing on the commercial expansion of VIZZ through new marketing strategies and telehealth options to boost prescription activity.